source
- STAT+: Capricor Therapeutics accuses Nippon Shinyaku of slow-walking plans on Duchenne drugCapricor Therapeutics has accused Nippon Shinyaku and its U.S. subsidiary of botching the rollout of a Duchenne muscular dystrophy treatment.STAT · 3mo ago↗ source
- Opinion: I’m fighting misinformation online. False hantavirus claims follow a now-familiar playbookThe cruise ship hantavirus outbreak is serious but limited. Online, it's another story.STAT · 3mo ago↗ source
- Lilly to invest extra $4.5B across Indiana manufacturingThe Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.BioPharma Dive · 3mo ago↗ source